Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 5: 1048 - 1058

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.05.011

Original Articles

Jianpi Yifei Tongluo recipe (健脾益肺通络方剂) attenuates inflammation by promoting the expression of interferon regulatory factor 4 in the rat model of chronic obstructive pulmonary disease

  • Wei WANG ,
  • Qi LONG ,
  • Ling FU ,
  • Haiqiao WU
Expand
  • Department of respiratory and critical care medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400038, China

Received date: 2024-03-22

  Accepted date: 2024-06-18

  Online published: 2025-09-15

Supported by

National Science Foundation for Distinguished Young Scholars of China to Intestinal Microflora-Mediated Regulation of Breast Regression Protein 39/chitinase-3-like Protein 1 Signaling pathway in the Intervention of Chronic Obstructive Pulmonary Disease by Invigorating Spleen Supplementing Lung and Relaxing Collaterals Method(81804074)

Fold

Abstract

OBJECTIVE: To examine the effects of the Jianpi Yifei Tongluo recipe (健脾益肺通络方剂, JYTR) on chronic obstructive pulmonary disease (COPD) within an animal model and to elucidate its anti-inflammatory mechanisms.

METHODS: In this study, we utilized cigarette smoke (CS) exposure and lipopolysaccharide (LPS)-induced models of COPD in rats to evaluate the effects of the JYTR on airway inflammation. Sprague-Dawley rats were randomly assigned to various groups: control, model, budesonide, synbiotics, and low, medium, and high JYTR. Pulmonary function was gauged using an animal volumetric tracer. Pathological alterations in lung tissue were examined under a light microscope. To ascertain cytokine production, we conducted enzyme-linked immunosorbent assay tests, and we employed Western blotting to measure the expression levels of interferon regulatory factor 4 (IRF4), arginase 1(Arg1), inducible nitric oxide synthase (iNOS), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IKB-α), and P65.

RESULTS: Compared to the control group, rats in the COPD model group exhibited significantly compromised pulmonary function and severe inflammatory pathology in the lungs. Treatment with budesonide, synbiotics, and the JYTR markedly improved pulmonary function and diminished the production of inflammatory cytokines transforming growth factor-beta (TGF-β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These improvements were particularly notable in the budesonide group and the high-dose JYTR group. Additionally, the JYTR increased the expression of IRF4 and upregulated the protein expression of Arg1, while concurrently downregulating the protein expression of iNOS, phosphorylated IKB-α, and phosphorylated P65.

CONCLUSION: Our current study reveals that JYTR can mitigate inflammatory lung injury, enhance lung function, and lower levels of inflammatory cytokines induced by CS or LPS exposure in COPD model rats. The mechanism behind its anti-inflammatory effect likely involves the regulation of IRF4 expression and M2 polarization through the nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway.

Key words： cigarette smoking; inflammation; pulmonary disease, chronic obstructive; interferon regulatory factors; Jianpi Yifei Tongluo recipe

Cite this article

Wei WANG , Qi LONG , Ling FU , Haiqiao WU . Jianpi Yifei Tongluo recipe (健脾益肺通络方剂) attenuates inflammation by promoting the expression of interferon regulatory factor 4 in the rat model of chronic obstructive pulmonary disease[J]. Journal of Traditional Chinese Medicine, 2025 , 45(5) : 1048 -1058 . DOI: 10.19852/j.cnki.jtcm.2025.05.011

References

1. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022; 10: 447-58.
2. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med 2020; 8: 585-96.
3. Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and Meta-analysis. East Mediterr Health J 2019; 25: 47-57.
4. Corhay JL, Bonhomme O, Heinen V, Moermans C, Louis R. Chronic obstructive pulmonary disease. A chronic inflammatory disease. Rev Med Liege 2022; 77: 295-301.
5. Rhee CK. Chronic obstructive pulmonary disease research by using big data. Clin Respir J 2021; 15: 257-63.
6. Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med 2020; 41: 421-38.
7. Zhang H, Li J, Yu X, et al. Effects of chinese medicine on patients with acute exacerbations of copd: study protocol for a randomized controlled trial. Trials 2019; 20: 735.
8. Burge AT, Cox NS, Abramson MJ, Holland AE. Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2020; 4: Cd012626.
9. Chan KH, Tsoi YYS, Mccall M. The effectiveness of Traditional Chinese Medicine (TCM) as an adjunct treatment on stable COPD patients: a systematic review and Meta-analysis. Evid Based Complement Alternat Med 2021; 2021: 5550332.
10. Yu XQ, Wang MH, Li JS, et al. Effect of comprehensive therapy based on Chinese medicine patterns on self-efficacy and effectiveness satisfaction in chronic obstructive pulmonary disease patients. Chin J Integr Med 2019; 25: 736-42.
11. Wang H, Hou Y, Ma X, et al. Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of Traditional Chinese Medicine, Bufei Jianpi granules: implication for copd drug discovery. Phytomedicine 2022; 98: 153963.
12. Wang S, Xiong LL, Ren W, Zhu CD, Li CY, Zhou Q. Effect of yifei jianpi recipe on airway inflammation and airway mucus hypersecretion of chronic obstructive pulmonary disease model rats. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2015; 35: 993-99.
13. Jefferies CA. Regulating IRFs in ifn driven disease. Front Immunol 2019; 10: 325.
14. Chen M, Wen X, Gao Y, et al. IRF-4 deficiency reduces inflammation and kidney fibrosis after folic acid-induced acute kidney injury. Int Immunopharmacol 2021; 100: 108142.
15. Zhang X, Artola-Boran M, Fallegger A, et al. IRF 4 expression is required for the immunoregulatory activity of conventional type 2 dendritic cells in settings of chronic bacterial infection and cancer. J Immunol 2020; 205: 1933-43.
16. Ngwa C, Mamun AA, Xu Y, Sharmeen R, Liu F. Phosphorylation of microglial IRF5 and IRF4 by IRAK4 regulates inflammatory responses to ischemia. Cells 2021: 10.
17. Bae S, Park PSU, Lee Y, et al. Myc-mediated early glycolysis negatively regulates proinflammatory responses by controlling IRF 4 in inflammatory macrophages. Cell Rep 2021; 35: 109264.
18. Song Y, Cui D, Mao P. A study on pathological changes and the potential role of growth factors in the airway wall remodeling of copd rat models. Zhong Hua Jie He He Hu Xi Za Zhi 2001; 24: 283-7.
19. Hu YX, Cui H, Fan L, et al. Resveratrol attenuates left ventricular remodeling in old rats with copd induced by cigarette smoke exposure and lps instillation. Can J Physiol Pharmacol 2013; 91: 1044-54.
20. Vernooy JH, Dentener MA, Van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002; 26: 152-9.
21. Mao J, Li Y, Li S, et al. Bufei jianpi granules reduce quadriceps muscular cell apoptosis by improving mitochondrial function in rats with chronic obstructive pulmonary disease. Evid Based Complement Alternat Med 2019; 2019: 1216305.
22. Hao D, Li Y, Shi J, Jiang J. Baicalin alleviates chronic obstructive pulmonary disease through regulation of hsp72-mediated JNK pathway. Mol Med 2021; 27: 53.
23. Ma J, Tian Y, Li J, et al. Effect of bufei yishen granules combined with electroacupuncture in rats with chronic obstructive pulmonary disease via the regulation of TLR-4/NF-κB signaling. Evid Based Complement Alternat Med 2019; 2019: 6708645.
24. Fan Y, Wen X, Zhang Q, et al. Effect of Traditional Chinese Medicine Bufei granule on stable chronic obstructive pulmonary disease: a systematic review and Meta-analysis based on existing evidence. Evid Based Complement Alternat Med 2020; 2020: 3439457.
25. Tang CY, Tang SL, Huang KF, Xu J, Yu H, Lin L. Jian-pi-yi-fei granule suppresses airway inflammation in mice induced by cigarette smoke condensate and lipopolysaccharide. Indian J Pharmacol 2019; 51: 263-8.
26. Xi C, Li F, Cheng W, et al. Application of Traditional Chinese and Western Medicine combined with chronic disease management in pulmonary rehabilitation and evaluation of efficacy. Am J Transl Res 2021; 13: 6372-81.
27. Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management. Med Clin North Am 2019; 103: 453-61.
28. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138: 16-27.
29. Rodrigues SO, Cunha C, Soares GMV, Silva PL, Silva AR, Gon?alves-De-Albuquerque CF. Mechanisms, pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals (Basel) 2021; 14: 979-1002.
30. Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin Sci (Lond) 2022; 136: 405-23.
31. Jin F, Zhang L, Chen K, et al. Effective-component compatibility of Bufei Yishen formula Ⅲ combined with electroacupuncture suppresses inflammatory response in rats with chronic obstructive pulmonary disease via regulating SIRT1/NF-κB signaling. Biomed Res Int 2022; 2022: 3360771.
32. Silva BSA, Lira FS, Ramos D, et al. Severity of COPD and its relationship with IL-10. Cytokine 2018; 106: 95-100.
33. Takiguchi H, Yang CX, Yang CWT, et al. Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures. Sci Rep 2021; 11: 8282.
34. Bazzan E, Turato G, Tinè M, et al. Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity. Respir Res 2017; 18: 40.
35. Arora S, Dev K, Agarwal B, Das P, Syed MA. Macrophages: their role, activation and polarization in pulmonary diseases. Immunobiology 2018; 223: 383-96.
36. Yamasaki K, Eeden SFV. Lung macrophage phenotypes and functional responses: Role in the pathogenesis of COPD. Int J Mol Sci 2018; 19: 1449-65.
37. Zhou F, Mei J, Han X, et al. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes. Acta Pharm Sin B 2019; 9: 973-85.
38. Liu L, Guo H, Song A, et al. Progranulin inhibits lps-induced macrophage M1 polarization via NF-кB and MAPK pathways. BMC Immunol 2020; 21: 32.
39. Fan L, Chen R, Li L, et al. Protective effect of Jianpiyifei Ⅱ granule against chronic obstructive pulmonary disease via NF-κB signaling pathway. Evid Based Complement Alternat Med 2018; 2018: 4265790.
40. Ferrante CJ, Leibovich SJ. Regulation of macrophage polarization and wound healing. Adv Wound Care (New Rochelle) 2012; 1: 10-6.
41. Chistiakov DA, Myasoedova VA, Revin VV, Orekhov AN, Bobryshev YV. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology 2018; 223: 101-11.
42. Zhu Y, Yang G. Molecular identification and functional characterization of IRF4 from common carp (cyprinus carpio. L) in immune response: a negative regulator in the IFN and NF-κB signalling pathways. BMC Vet Res 2022; 18: 106.
Options
Outlines

/

〈 〉